Original article. Pharmacodynamics of dry powder formulations of salbutamol for delivery by inhalation

1. Rees PJ, Clark TJ, Moren F. The importance of particle size in responses to inhaled bronchodilators. Eur. J. Respir. Dis. 1982; 63:73-8.Search in Google Scholar

2. Zanen P, Go TL, Lammers JWJ. The optimal particle size for β2-adrenergic aerosols in mild asthmatics. Int. J. Pharm. 1994; 107: 211-7.Search in Google Scholar

3. Zanen P, Go TL, Lammers JWJ. Optimal particle size for β2-agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax. 1996; 51: 977-80.10.1136/thx.51.10.977Search in Google Scholar

4. Chrystyn, H., Is total particle dose more important than particle distribution? Respir. Med. 1997; 91:17-9.Search in Google Scholar

5. Newman SP, Pavia D, Moren F, Sheahan NF, Clarke SW. Deposition of pressurised aerosols in the human respiratory tract. Thorax. 1981; 36:52-5.10.1136/thx.36.1.52Search in Google Scholar

6. Mechlor R, Biddiscomb MF, Mak VHF, Spiro SG. Lung deposition patterns of directly labelled salbutamol in normal subjects and inpatients with reversible airflow obstruction. Thorax. 1993; 48:506-11.10.1136/thx.48.5.506Search in Google Scholar

7. Newman SP, Wilding IR, Hirst PH. Human lung deposition data: The bridge between in vitro and clinical evaluations for inhaled drug products?. Int J Pharm. 2000; 208:49-60.10.1016/S0378-5173(00)00538-XSearch in Google Scholar

8. Tomlinson HS, Corlett SA, Allen MB, Chrystyn H. Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge. Br J Clin Pharm. 2005; 60:605-10.10.1111/j.1365-2125.2005.02499.xSearch in Google Scholar

9. National Heart Lung and Blood Institute. National asthma education and prevention program expert panel report 3: guidelines for the diagnosis and management for asthma. 2007. [cited 2010 April 8]. Available from: http://www.nhlbi.nih.gov.Search in Google Scholar

10. Weda M, Zanen P, De Boer AH, Gjaltema D, Ajaoud A, Barends DM, et al. Equivalence testing of salbutamol dry powder inhalers: In vitro impaction results versus in vivo efficacy. In J Pharm. 2002; 249:247-55.10.1016/S0378-5173(02)00533-1Search in Google Scholar

11. British Pharmacopoeia. 2010. London: The Stationery Office (CD-ROM accessed 1 January 2010).Search in Google Scholar

12. Srichana T, Suedee R, Srisudjai P. Application of spectrofluorometry for evaluation of dry powder inhalers in vitro. Pharmazie. 2003; 58:125-9.Search in Google Scholar

13. National Asthma Council Australia. Asthma Management Handbook (Online). National Asthma Council Australia Ltd. [cited 2010 April 8].Available from: http://www.nationalasthma.org.au/cms/index.phpSearch in Google Scholar

14. International Conference on Harmonization (ICH). Good Clinical Practice Guidelines, Minister of Public Health, Therapeutic Directorate, Health Canada, Ontario; 1996.Search in Google Scholar

15. Srichana T, Suedee R, Tanmanee N, Muanpanarai D, Marriott C. The correlation of urinary levels of albuterol and its metabolites isomers following inhalation from a dry powder inhaler and in vitro particle size characterisation. Pulm.Pharmacol. 2007; 20:36-45.Search in Google Scholar

16. Srichana T, Brain A, Marriot C. A study of Drug-carrier interaction in dry powder inhaler formulation using the Andersen Cascade Impactor, X-ray microanalysis and time of flight aerosol beam spectrometry (TOFABS). Chem. Pharm. Bull. 2000; 48:167-74.Search in Google Scholar